Alan Parker
(Former)
1 - 6 out of 6Page size: 10
Publications
- 2015
- Published
- 2005
- Published
Allogeneic stem cell transplantation using a reduced intensity conditioning (RIC) regimen has the capacity to produce durable remissions and long term disease-free survival in patients with high risk acute myeloid leukemia (AML).
Gulnaz Begum, Alan Parker & Charles Craddock, 2005, In: Blood. 106, 11, p. 332a-332aResearch output: Contribution to journal › Article
- 2003
- Published
Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins
Alan Parker, Kerry Fisher, Paul Murray & Leonard Seymour, 1 Mar 2003, In: Journal of Drug Targeting. 11, p. 53-59 7 p.Research output: Contribution to journal › Article
- 2002
- Published
Role of non-myeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
Alan Parker, Ronjon Chakraverty, Charles Craddock, 1 Oct 2002, In: Journal of Clinical Oncology. 20, 19, p. 4022-4031 10 p.Research output: Contribution to journal › Article › peer-review
- Published
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non-myeloblative conditioning regimen
Ronjon Chakraverty, Charles Craddock, Alan Parker & 1 others, , 1 Feb 2002, In: Blood. 99, 3, p. 1071-1078 8 p.Research output: Contribution to journal › Article
- Published
Non-myeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders
Charles Craddock, Alan Parker, 1 Jan 2002, In: Blood. 100, p. 3121-3127 7 p.Research output: Contribution to journal › Article